{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,23]],"date-time":"2026-10-23T19:07:28Z","timestamp":1792782448853,"version":"4.5.0"},"reference-count":41,"publisher":"Wiley","issue":"8","license":[{"start":{"date-parts":[[2015,12,15]],"date-time":"2015-12-15T00:00:00Z","timestamp":1450137600000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/onlinelibrary.wiley.com\/termsAndConditions#vor"}],"funder":[{"name":"Ministry of Education, Culture, Sports, Science and Technology, Japan and Hidaka Research Projects in Saitama Medical University","id":[{"id":"https:\/\/ror.org\/048rj2z13","id-type":"ROR","asserted-by":"crossref"}]}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Intl Journal of Cancer"],"published-print":{"date-parts":[[2016,4,15]]},"abstract":"<jats:p>\n                    Folate receptor alpha (FRA) is a GPI\u2010anchored glycoprotein and encoded by the\n                    <jats:italic>FOLR1<\/jats:italic>\n                    gene. High expression of FRA is observed in specific malignant tumors of epithelial origin, including ovarian cancer, but exhibits very limited normal tissue expression, making it as an attractive target for the ovarian cancer therapy. FRA is known to shed from the cell surface into the circulation which allows for its measurement in the serum of patients. Recently, methods to detect the soluble form of FRA have been developed and serum FRA (sFRA) is considered a highly promising biomarker for ovarian cancer. We prospectively investigated the levels of sFRA in patients clinically suspected of having malignant ovarian tumors. A total of 231 patients were enrolled in this study and analyzed for sFRA as well as tumor expression of FRA by immunohistochemistry. High sFRA was predominantly observed in epithelial ovarian cancer patients, but not in patients with benign or borderline gynecological disease or metastatic ovarian tumors from advanced colorectal cancers. Levels of sFRA were highly correlated to clinical stage, tumor grade and histological type and demonstrated superior accuracy for the detection of ovarian cancer than did serum CA125. High sFRA was significantly associated with shorter progression\u2010free survival in both early and advanced ovarian cancer patients. Finally, tumor FRA expression status was strongly correlated with sFRA levels. Taken together, these data suggest that sFRA might be a useful noninvasive serum biomarkers for future clinical trials assessing FRA\u2010targeted therapy.\n                  <\/jats:p>","DOI":"10.1002\/ijc.29937","type":"journal-article","created":{"date-parts":[[2015,11,23]],"date-time":"2015-11-23T18:51:13Z","timestamp":1448304673000},"page":"1994-2002","source":"Crossref","is-referenced-by-count":91,"title":["Serum folate receptor alpha as a biomarker for ovarian cancer: Implications for diagnosis, prognosis and predicting its local tumor expression"],"prefix":"10.1002","volume":"138","author":[{"given":"Akira","family":"Kurosaki","sequence":"first","affiliation":[{"name":"Department of Gynecologic Oncology Saitama Medical University International Medical Center Hidaka Japan"},{"name":"Gynecologic Oncology Translational Research Unit, Project Research Division, Research Center for Genomic Medicine Saitama Medical University Hidaka Japan"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kosei","family":"Hasegawa","sequence":"additional","affiliation":[{"name":"Department of Gynecologic Oncology Saitama Medical University International Medical Center Hidaka Japan"},{"name":"Gynecologic Oncology Translational Research Unit, Project Research Division, Research Center for Genomic Medicine Saitama Medical University Hidaka Japan"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Tomomi","family":"Kato","sequence":"additional","affiliation":[{"name":"Department of Pathology Saitama Medical University International Medical Center Hidaka Japan"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kenji","family":"Abe","sequence":"additional","affiliation":[{"name":"Department of Research and Development EIDIA Co. Ltd Inashiki Japan"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Tatsuya","family":"Hanaoka","sequence":"additional","affiliation":[{"name":"Department of Gynecologic Oncology Saitama Medical University International Medical Center Hidaka Japan"},{"name":"Gynecologic Oncology Translational Research Unit, Project Research Division, Research Center for Genomic Medicine Saitama Medical University Hidaka Japan"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Akiko","family":"Miyara","sequence":"additional","affiliation":[{"name":"Gynecologic Oncology Translational Research Unit, Project Research Division, Research Center for Genomic Medicine Saitama Medical University Hidaka Japan"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Daniel J.","family":"O'Shannessy","sequence":"additional","affiliation":[{"name":"Department of Translation Medicine and Diagnostics Morphotek, Inc, Exton  PA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Elizabeth B.","family":"Somers","sequence":"additional","affiliation":[{"name":"Department of Translation Medicine and Diagnostics Morphotek, Inc, Exton  PA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Masanori","family":"Yasuda","sequence":"additional","affiliation":[{"name":"Department of Pathology Saitama Medical University International Medical Center Hidaka Japan"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Tetsuo","family":"Sekino","sequence":"additional","affiliation":[{"name":"Department of Research and Development EIDIA Co. Ltd Inashiki Japan"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Keiichi","family":"Fujiwara","sequence":"additional","affiliation":[{"name":"Department of Gynecologic Oncology Saitama Medical University International Medical Center Hidaka Japan"},{"name":"Gynecologic Oncology Translational Research Unit, Project Research Division, Research Center for Genomic Medicine Saitama Medical University Hidaka Japan"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"311","published-online":{"date-parts":[[2015,12,15]]},"reference":[{"key":"e_1_2_7_2_1","unstructured":"American Cancer Society. Cancer facts and figures [http:\/\/www.cancer.org\/research\/cancerfactsstatistics\/cancerfactsfigures2015\/index].2015."},{"key":"e_1_2_7_3_1","doi-asserted-by":"publisher","DOI":"10.1097\/PGP.0b013e3182774562"},{"key":"e_1_2_7_4_1","doi-asserted-by":"publisher","DOI":"10.1371\/journal.pone.0006292"},{"key":"e_1_2_7_5_1","doi-asserted-by":"publisher","DOI":"10.1007\/s11605-013-2389-9"},{"key":"e_1_2_7_6_1","doi-asserted-by":"publisher","DOI":"10.1093\/annonc\/mdr154"},{"key":"e_1_2_7_7_1","doi-asserted-by":"publisher","DOI":"10.1002\/ijc.11472"},{"key":"e_1_2_7_8_1","doi-asserted-by":"publisher","DOI":"10.3748\/wjg.v21.i4.1216"},{"key":"e_1_2_7_9_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.ygyno.2006.12.035"},{"key":"e_1_2_7_10_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.addr.2004.01.001"},{"key":"e_1_2_7_11_1","doi-asserted-by":"publisher","DOI":"10.1186\/1757-2215-6-29"},{"key":"e_1_2_7_12_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.ygyno.2007.05.018"},{"key":"e_1_2_7_13_1","doi-asserted-by":"publisher","DOI":"10.1002\/(SICI)1097-0215(19980417)79:2<121::AID-IJC4>3.0.CO;2-V"},{"key":"e_1_2_7_14_1","doi-asserted-by":"publisher","DOI":"10.1158\/1078-0432.CCR-06-1343"},{"key":"e_1_2_7_15_1","doi-asserted-by":"publisher","DOI":"10.18632\/oncotarget.519"},{"key":"e_1_2_7_16_1","doi-asserted-by":"publisher","DOI":"10.1067\/mtc.2001.111176"},{"key":"e_1_2_7_17_1","doi-asserted-by":"publisher","DOI":"10.1073\/pnas.93.1.136"},{"key":"e_1_2_7_18_1","doi-asserted-by":"publisher","DOI":"10.1007\/s10555-014-9539-8"},{"key":"e_1_2_7_19_1","first-page":"6","article-title":"Preclinical evaluation of MORAb\u2010003, a humanized monoclonal antibody antagonizing receptor alpha","volume":"7","author":"Ebel W","year":"2007","journal-title":"Cancer Immunity"},{"key":"e_1_2_7_20_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.ygyno.2013.03.002"},{"key":"e_1_2_7_21_1","doi-asserted-by":"publisher","DOI":"10.1002\/ijc.22853"},{"key":"e_1_2_7_22_1","doi-asserted-by":"publisher","DOI":"10.1158\/0008-5472.CAN-07-0033"},{"key":"e_1_2_7_23_1","first-page":"857","article-title":"Preclinical evaluation of (99m)Tc\u2010EC20 for imaging folate receptor\u2010positive tumors","volume":"45","author":"Reddy JA","year":"2004","journal-title":"J Nucl Med"},{"key":"e_1_2_7_24_1","doi-asserted-by":"publisher","DOI":"10.1007\/s10637-014-0180-8"},{"key":"e_1_2_7_25_1","doi-asserted-by":"publisher","DOI":"10.1158\/1078-0432.CCR-06-0992"},{"key":"e_1_2_7_26_1","doi-asserted-by":"publisher","DOI":"10.1158\/1535-7163.MCT-14-1095"},{"key":"e_1_2_7_27_1","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.2013.49.7685"},{"key":"e_1_2_7_28_1","doi-asserted-by":"publisher","DOI":"10.1093\/annonc\/mdu024"},{"key":"e_1_2_7_29_1","doi-asserted-by":"publisher","DOI":"10.1371\/journal.pone.0096542"},{"key":"e_1_2_7_30_1","doi-asserted-by":"publisher","DOI":"10.18632\/oncotarget.412"},{"key":"e_1_2_7_31_1","doi-asserted-by":"publisher","DOI":"10.1002\/1097-0142(1950)3:1<32::AID-CNCR2820030106>3.0.CO;2-3"},{"key":"e_1_2_7_32_1","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMra041842"},{"key":"e_1_2_7_33_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.clinbiochem.2013.03.010"},{"key":"e_1_2_7_34_1","first-page":"CD006119","article-title":"Evaluation of follow\u2010up strategies for patients with epithelial ovarian cancer following completion of primary treatment","author":"Kew F","year":"2011","journal-title":"Cochrane Database Syst Rev"},{"key":"e_1_2_7_35_1","doi-asserted-by":"publisher","DOI":"10.1007\/s00404-007-0381-x"},{"key":"e_1_2_7_36_1","doi-asserted-by":"publisher","DOI":"10.1097\/00004728-200411000-00018"},{"key":"e_1_2_7_37_1","doi-asserted-by":"publisher","DOI":"10.2214\/AJR.09.2985"},{"key":"e_1_2_7_38_1","doi-asserted-by":"publisher","DOI":"10.1007\/s00330-005-2882-y"},{"key":"e_1_2_7_39_1","doi-asserted-by":"publisher","DOI":"10.1097\/RLU.0000000000000657"},{"key":"e_1_2_7_40_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.ejogrb.2004.04.034"},{"key":"e_1_2_7_41_1","unstructured":"Eisai Announces Results of Phase III Study of Anticancer Agent Farletuzumab in Patients with Relapsed Platinum\u2010Sensitive Ovarian Cancer [News Release]. Tokyo Japan: Eisai Co. Ltd. 11 January 2013.http:\/\/www.eisai.com\/news\/news201305.html(last accessed on 8 October2014)."},{"issue":"8","key":"e_1_2_7_42_1","first-page":"11","article-title":"Phase 3 double\u2010blind, placebo\u2010controlled study of weekly farletuzumab with carboplatin\/taxane in subjects with platinum sensitive ovarian cancer in first relapse","volume":"23","author":"Vergote I","year":"2013","journal-title":"Int J Gynecol Cancer"}],"container-title":["International Journal of Cancer"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.wiley.com\/onlinelibrary\/tdm\/v1\/articles\/10.1002%2Fijc.29937","content-type":"unspecified","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/pdf\/10.1002\/ijc.29937","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2023,10,5]],"date-time":"2023-10-05T14:18:58Z","timestamp":1696515538000},"score":1,"resource":{"primary":{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/10.1002\/ijc.29937"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2015,12,15]]},"references-count":41,"journal-issue":{"issue":"8","published-print":{"date-parts":[[2016,4,15]]}},"alternative-id":["10.1002\/ijc.29937"],"URL":"https:\/\/doi.org\/10.1002\/ijc.29937","archive":["Portico"],"relation":{},"ISSN":["0020-7136","1097-0215"],"issn-type":[{"value":"0020-7136","type":"print"},{"value":"1097-0215","type":"electronic"}],"subject":[],"published":{"date-parts":[[2015,12,15]]}}}